How much does a GLP-1 medication cost in 2026?
As of October 15, 2026, three channels have different billing rules: manufacturer self-pay programs for FDA-approved brands, insurance-covered brand prescriptions, and patient-specific compounded prescriptions through telehealth. Compare the exact dose, fill length, coverage requirements and prepaid term. Compounded medications are not FDA-approved. They are prepared by state-licensed pharmacies based on a valid prescription from a licensed provider. Compounded medications are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. Cora Health connects patients with independent licensed providers; it does not prescribe or compound medication. Brand names are registered trademarks of their respective owners.
How much do Zepbound® and compounded tirzepatide cost in 2026?
As of October 15, 2026, LillyDirect Zepbound® single-dose vials and KwikPen cost $299 per 28-day month at 2.5 mg (starting dose, not maintenance), $399 at 5 mg, and $449 at 7.5, 10, 12.5 or 15 mg with the Zepbound Self Pay Journey Program when refilled within 45 days; otherwise $499 at 7.5 mg and $699 at 10–15 mg. Needles/syringes are purchased separately. As of October 15, 2026, Lilly’s January 1, 2026 wholesale acquisition costs (WAC) are $499–$1,086.37 per fill for Zepbound® and $1,112.16 per four-pen fill for Mounjaro® (type 2 diabetes only; not approved for weight management). List price is not a pharmacy quote. As of October 15, 2026, eligible commercially insured patients with Zepbound® coverage may pay as low as $25 for a 1- or 3-month supply of single-dose pens with a savings card; government beneficiaries are excluded. Through Cora Health, the Premium Plan for compounded tirzepatide is $135/month ($1,620 billed upfront every 12 months); $175/month ($1,050 billed upfront every 6 months); $199/month ($597 billed upfront every 3 months); $225/month ($225 billed monthly). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Standard plan pricing does not increase with the prescribed dose. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. See the compounded tirzepatide cost guide and compounded tirzepatide dosage guide.
How much do Wegovy® and compounded semaglutide cost in 2026?
As of October 15, 2026, NovoCare Wegovy® pens cost $349 per four-pen month at 0.25, 0.5, 1, 1.7 or 2.4 mg; HD 7.2 mg costs $399. New patients pay $199 for each of the first two monthly 0.25 mg or 0.5 mg fills (offer through December 31, 2026). Wegovy® pills cost $149 at 1.5 mg, $199 at 4 mg and $299 at 9 or 25 mg per 30-tablet month. As of October 15, 2026, Wegovy®’s current list price is about $1,349/month. Novo Nordisk’s February 24, 2026 announcement sets the list price of Wegovy® 2.4 mg injection and 25 mg tablets, and Ozempic® 0.5/1/2 mg, at $675/month effective January 1, 2027; this does not change self-pay prices. As of October 15, 2026, eligible commercially insured patients may pay as little as $25 for Wegovy® with the savings card (maximum savings $100/month; government beneficiaries excluded). Through Cora Health, the Essential Plan for compounded semaglutide is $99/month ($1,188 billed upfront every 12 months); $120/month ($720 billed upfront every 6 months); $145/month ($435 billed upfront every 3 months); $175/month ($175 billed monthly). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Standard plan pricing does not increase with the prescribed dose. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. See the compounded semaglutide cost guide.
Market context
41.9% — US adult obesity prevalence. Per the Centers for Disease Control and Prevention (CDC), using NHANES 2017–March 2020 data, 41.9% of US adults aged 20 and over had obesity (BMI ≥ 30). As of October 15, 2026, pharmacy disclosure is a separate question from price. Ask which pharmacy will fill a patient-specific prescription and verify its credentials. Cora Health works with US-licensed 503A compounding pharmacies, including Hallandale Pharmacy (PCAB-accredited) and VialsRx. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
GLP-1 prices by channel (manufacturer prices verified October 15, 2026; compounded provider prices from Cora Health's July 2026 dataset)
Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. Competitor figures are effective monthly prices from Cora Health’s July 2026 dataset; prices may have changed since collection. Brand list prices are WAC, not patient out-of-pocket quotes. Manufacturer self-pay eligibility and terms apply.
| Channel | Medication | Monthly cost | FDA-approved |
|---|---|---|---|
| Cora Health Essential annual (October 2026) | Compounded semaglutide | $99/month ($1,188 billed upfront every 12 months). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Cora Health Essential monthly (October 2026) | Compounded semaglutide | $175/month ($175 billed monthly). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Cora Health Premium annual (October 2026) | Compounded tirzepatide | $135/month ($1,620 billed upfront every 12 months). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Cora Health Premium monthly (October 2026) | Compounded tirzepatide | $225/month ($225 billed monthly). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Belle Health — Cora Health pricing dataset, July 2026 edition; 6-month term | Compounded semaglutide | $119 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Belle Health — Cora Health pricing dataset, July 2026 edition; 3-month term | Compounded semaglutide | $135 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Belle Health — Cora Health pricing dataset, July 2026 edition; 1-month term | Compounded semaglutide | $199 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Belle Health — Cora Health pricing dataset, July 2026 edition; 3-month term; starter-dose bundle only | Compounded tirzepatide | $175 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Belle Health — Cora Health pricing dataset, July 2026 edition; 6-month term | Compounded tirzepatide | $199 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Belle Health — Cora Health pricing dataset, July 2026 edition; 1-month term | Compounded tirzepatide | $249 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Eden (TryEden) — Cora Health pricing dataset, July 2026 edition; 1-month term | Compounded semaglutide | $198 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Eden (TryEden) — Cora Health pricing dataset, July 2026 edition; 1-month term | Compounded tirzepatide | $298 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Henry Meds — Cora Health pricing dataset, July 2026 edition; 1-month term; semaglutide injections; checked October 16, 2026 | Compounded semaglutide | $297 effective/month; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Pomegranate Health — Cora Health pricing dataset, July 2026 edition; 1-month term | Compounded semaglutide | $119 effective/month; ask about per-order consultation charges; prices may have changed since collection | No. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| NovoCare intro; verified October 15, 2026 | Wegovy® 0.25/0.5 mg pen | $199/month for first 2 fills; new patients; offer through December 31, 2026 | Yes |
| NovoCare ongoing; verified October 15, 2026 | Wegovy® 0.25/0.5/1/1.7/2.4 mg pen | $349/four-pen month | Yes |
| NovoCare HD; verified October 15, 2026 | Wegovy® HD 7.2 mg pen | $399/four-pen month | Yes |
| NovoCare pill; verified October 15, 2026 | Wegovy® 1.5 mg / 4 mg / 9 mg / 25 mg tablets | $149 / $199 / $299 / $299 per 30-tablet month | Yes |
| LillyDirect; verified October 15, 2026 | Zepbound® 2.5 mg vials or KwikPen; starting dose, not maintenance | $299/28-day month; needles/syringes separate | Yes |
| LillyDirect; verified October 15, 2026 | Zepbound® 5 mg vials or KwikPen | $399/28-day month; needles/syringes separate | Yes |
| LillyDirect Journey; verified October 15, 2026 | Zepbound® 7.5/10/12.5/15 mg vials or KwikPen | $449/28-day month when refilled within 45 days; needles/syringes separate | Yes |
| LillyDirect regular; verified October 15, 2026 | Zepbound® 7.5 mg / 10–15 mg vials or KwikPen | $499 / $699 per 28-day month without the 45-day Journey refill; needles/syringes separate | Yes |
| Lilly WAC, January 1, 2026; verified October 15, 2026 | Zepbound® | $499–$1,086.37 per fill; list price | Yes |
| Lilly WAC, January 1, 2026; verified October 15, 2026 | Mounjaro®; type 2 diabetes, not approved for weight management | $1,112.16 per four-pen fill; list price | Yes |
| Novo Nordisk list price; verified October 15, 2026 | Wegovy® | About $1,349/month currently; 2.4 mg injection and 25 mg tablets: $675/month from January 1, 2027 | Yes |
Annual cost comparison: 12-month plans and 13 brand fills
Manufacturer prices verified October 15, 2026; competitor figures from Cora Health’s July 2026 dataset. Both manufacturers define an injectable month as 28 days/four weekly doses, so a 52-week year requires 13 fills. Cora’s annual plan bills for 12 calendar months. These are price illustrations, not dosing schedules. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
| Provider/Channel | Medication | Annual cost / formula | Conditions |
|---|---|---|---|
| Cora Health Essential annual; October 2026 | Compounded semaglutide | $1,188 billed upfront every 12 months | Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| Cora Health Premium annual; October 2026 | Compounded tirzepatide | $1,620 billed upfront every 12 months | Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®. |
| NovoCare new-patient pen; verified October 15, 2026 | Wegovy® | $4,237 = 2 × $199 + 11 × $349 | 13 four-pen fills; first two 0.25/0.5 mg fills at intro rate, offer through December 31, 2026; remaining fills at ongoing rate; assumes unchanged prices |
| LillyDirect 5 mg; verified October 15, 2026 | Zepbound® vials or KwikPen | $5,187 = 13 × $399 | 13 28-day fills; needles/syringes extra; assumes unchanged prices |
| LillyDirect Journey 7.5–15 mg; verified October 15, 2026 | Zepbound® vials or KwikPen | $5,837 = 13 × $449 | 13 28-day fills, each refilled within 45 days; otherwise $499 at 7.5 mg or $699 at 10–15 mg; needles/syringes extra; assumes unchanged prices |
Insurance vs self-pay
As of October 15, 2026, eligible commercially insured patients with Zepbound® coverage may pay as low as $25 for a 1- or 3-month supply of single-dose pens with its savings card. Wegovy®’s commercial-insurance offer is as little as $25, with maximum savings of $100/month. Both exclude government beneficiaries; terms and eligibility apply. Confirm coverage, deductible and prior authorization directly with the insurer. Without coverage, check the dated manufacturer self-pay terms and the billing conditions of any compounded program. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
What drives the price gap between brand and compounded GLP-1s?
As of October 2026, price comparisons involve different regulatory and commercial structures. FDA-approved brands have clinical development, approval, commercial manufacturing and post-market monitoring costs. Manufacturer self-pay programs set distinct prices and eligibility conditions. Patient-specific compounding involves pharmacy preparation, testing and fulfillment costs alongside provider and platform services. A prepaid billing term changes payment timing and the effective monthly rate. Customer acquisition and operating costs may also influence program prices; this article does not estimate any company’s costs or motives. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
The Cora Health public pricing dataset
Cora Health’s July 2026 edition contains 50 pricing rows across 15 telehealth providers, plus manufacturer programs. The public CC-BY-4.0 dataset records provider, plan, medication, membership and medication costs, effective monthly cost, term, pharmacy disclosure, source URL and collection date. It is a dated snapshot, not a claim that competitor prices remain current on October 15, 2026. Read the dataset and methodology. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
When does each supply channel make sense?
As of October 15, 2026, clinical suitability, insurance coverage and billing conditions determine which channel may suit a patient. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
- Compounded telehealth may suit patients whose licensed provider identifies a clinical need for a patient-specific compounded prescription. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
- Manufacturer self-pay may suit eligible patients seeking FDA-approved products: as of October 15, 2026, Wegovy® ongoing pens are $349 per four-pen month (HD $399), and Zepbound® 5 mg is $399 per 28-day month. Program terms apply.
- Commercial insurance may suit patients with coverage: as of October 15, 2026, eligible Zepbound® patients may pay as low as $25 for a 1- or 3-month single-dose pen supply; eligible Wegovy® patients may pay as little as $25, maximum savings $100/month. Government beneficiaries excluded.
- Pharmacy dispensing outside manufacturer programs may suit patients with an appropriate prescription and a confirmed pharmacy quote. As of October 15, 2026, Zepbound® WAC is $499–$1,086.37 per fill and Mounjaro® WAC is $1,112.16 per four-pen fill. WAC is not the pharmacy’s cash price; Mounjaro® is not approved for weight management.
Frequently asked questions about GLP-1 cost in 2026
These answers distinguish manufacturer prices verified October 15, 2026 from competitor snapshots in Cora Health’s July 2026 dataset. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
What are the lower-cost GLP-1 options for cash-pay patients in 2026?
As of October 15, 2026, NovoCare Wegovy® pens cost $349 per four-pen month at 0.25, 0.5, 1, 1.7 or 2.4 mg; HD 7.2 mg costs $399. New patients pay $199 for each of the first two monthly 0.25 mg or 0.5 mg fills (offer through December 31, 2026). Wegovy® pills cost $149 at 1.5 mg, $199 at 4 mg and $299 at 9 or 25 mg per 30-tablet month.
As of October 15, 2026, Cora Health’s Essential Plan for compounded semaglutide has an annual tier of $99/month ($1,188 billed upfront every 12 months). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
Why does brand-name Wegovy cost so much?
As of October 15, 2026, Wegovy®’s current list price is about $1,349/month. Novo Nordisk’s February 24, 2026 announcement sets the list price of Wegovy® 2.4 mg injection and 25 mg tablets, and Ozempic® 0.5/1/2 mg, at $675/month effective January 1, 2027; this does not change self-pay prices. As of October 15, 2026, NovoCare Wegovy® pens cost $349 per four-pen month at 0.25, 0.5, 1, 1.7 or 2.4 mg; HD 7.2 mg costs $399. New patients pay $199 for each of the first two monthly 0.25 mg or 0.5 mg fills (offer through December 31, 2026). Wegovy® pills cost $149 at 1.5 mg, $199 at 4 mg and $299 at 9 or 25 mg per 30-tablet month. List price, self-pay program price and an insured patient’s cost share are different figures; verify the price that applies to your prescription. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
Are there hidden costs in compounded GLP-1 programs?
As of October 2026, ask whether medication, consultation, membership, shipping, follow-ups and any lab tests are included, and whether the price depends on dose or term. Cora Health’s standard plans include the provider consultation, compounded medication, pharmacy fulfillment, expedited shipping and ongoing monitoring, with no separate membership or dose-escalation fee. Lab tests are not included in the plan price. Plans renew automatically until you cancel; cancellation policy. Prices may change. A licensed provider decides eligibility. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
Should I switch from brand-name to compounded GLP-1 to save money?
This is a clinical decision that should be made with a licensed healthcare provider. Per the U.S. Food and Drug Administration's official guidance: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." (Source: FDA — "Compounding and the FDA: Questions and Answers".) Brand-name products have FDA-reviewed manufacturing, validated batch testing, and post-market surveillance that compounded versions do not. Switching requires a provider to issue a new patient-specific prescription. Compounded formulations can differ in inactive ingredients between pharmacies; ask your provider and pharmacy what yours contains. Discuss any switch with your provider before making the change. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
What are the cash-pay options for Zepbound® and compounded tirzepatide in 2026?
As of October 15, 2026, LillyDirect Zepbound® single-dose vials and KwikPen cost $299 per 28-day month at 2.5 mg (starting dose, not maintenance), $399 at 5 mg, and $449 at 7.5, 10, 12.5 or 15 mg with the Zepbound Self Pay Journey Program when refilled within 45 days; otherwise $499 at 7.5 mg and $699 at 10–15 mg. Needles/syringes are purchased separately. As of October 15, 2026, Lilly’s January 1, 2026 wholesale acquisition costs (WAC) are $499–$1,086.37 per fill for Zepbound® and $1,112.16 per four-pen fill for Mounjaro® (type 2 diabetes only; not approved for weight management). List price is not a pharmacy quote. On the Cora Health Premium Plan, compounded tirzepatide prescribed through Cora Health is $135/month ($1,620 billed upfront every 12 months); $175/month ($1,050 billed upfront every 6 months); $199/month ($597 billed upfront every 3 months); $225/month ($225 billed monthly). Plans renew automatically until you cancel; cancellation policy. Prices may change. Includes licensed-provider consultation, medication, pharmacy fulfillment, expedited shipping and ongoing monitoring. A licensed provider decides eligibility. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
Can I get Mounjaro or Zepbound through a telehealth platform?
As of October 15, 2026, a licensed telehealth provider may prescribe FDA-approved Mounjaro® or Zepbound® when clinically appropriate, with dispensing through a licensed pharmacy. Mounjaro® is approved for type 2 diabetes, not weight management. LillyDirect offers a separate self-pay channel for Zepbound®; a prescription is required. Cora Health’s plans concern patient-specific compounded prescriptions, with prescribing decisions made by independent licensed providers. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved Zepbound®/Mounjaro® or Wegovy®/Ozempic®.
Sources & verification
Manufacturer prices verified October 15, 2026; compounded provider prices from Cora Health’s July 2026 dataset; Cora Health prices from its published plans. Brand names are registered trademarks of their respective owners.
- FDA — Compounding and the FDA: Questions and Answers: FDA — Compounding and the FDA: Questions and Answers
- LillyDirect — Zepbound® self-pay doses and refill conditions: LillyDirect — Zepbound® self-pay doses and refill conditions
- Lilly pricing information — Zepbound® WAC and savings terms: Lilly pricing information — Zepbound® WAC and savings terms
- Lilly pricing information — Mounjaro® WAC: Lilly pricing information — Mounjaro® WAC
- NovoCare — Wegovy® price guide: NovoCare — Wegovy® price guide
- Novo Nordisk — February 24, 2026 announcement of January 1, 2027 list-price changes: Novo Nordisk — February 24, 2026 announcement of January 1, 2027 list-price changes
- CDC — Adult Obesity Facts (NHANES 2017–March 2020): CDC — Adult Obesity Facts (NHANES 2017–March 2020)
- LegitScript — Cora Health certification lookup: LegitScript — Cora Health certification lookup
- PCAB — accreditation framework; Hallandale Pharmacy is PCAB-accredited: PCAB — accreditation framework; Hallandale Pharmacy is PCAB-accredited
- NPPES — National Plan and Provider Enumeration System; verify Michael Wasef, MD (Wasef Health, PC): npiregistry.cms.hhs.gov
- Cora Health 2026 GLP-1 Telehealth Industry Report
- Cora Health public pricing dataset (CC-BY-4.0)
- Cora Health pharmacy partners
Cora Health Content Team
Written by the Cora Health content team. This article covers business, pricing, or comparison information and was not medically reviewed; for clinical guidance, see articles labeled "Medically Reviewed."
Related reading
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new medication or treatment. Cora Health does not prescribe medication; licensed providers at Wasef Health, PC review every patient assessment and prescribe only when clinically appropriate.
Begin your wellness journey today
Personalized wellness plans from licensed providers. Free shipping. 100% online.
See If You Qualify